Edition:
United States

AstraZeneca PLC (AZN.N)

AZN.N on New York Stock Exchange

33.96USD
10:52am EDT
Change (% chg)

$0.01 (+0.03%)
Prev Close
$33.95
Open
$33.90
Day's High
$34.09
Day's Low
$33.88
Volume
242,411
Avg. Vol
938,497
52-wk High
$35.03
52-wk Low
$25.56

AZN.N

Chart for AZN.N

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 0.77
Market Cap(Mil.): $84,626.79
Shares Outstanding(Mil.): 2,531.28
Dividend: 0.95
Yield (%): 4.12

Financials

  AZN.N Industry Sector
P/E (TTM): 25.36 14.27 17.29
EPS (TTM): 1.34 -- --
ROI: 7.30 -7.68 -5.84
ROE: 24.45 -7.30 -5.23

AstraZeneca asthma shot hits goal but diabetes drug lags rival

LONDON AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.

4:29am EDT

UPDATE 1-AstraZeneca asthma shot hits goal but diabetes drug lags rival

* Bydureon fails to show heart risk reduction in diabetes (Wraps asthma and diabetes drug news)

4:23am EDT

BRIEF-Genomic Vision to enter into technological collaboration with AstraZeneca in oncology

* GENOMIC VISION TO ENTER INTO TECHNOLOGICAL COLLABORATION WITH ASTRAZENECA IN ONCOLOGY

2:13am EDT

BRIEF-Astrazeneca says Bydureon EXSCEL trial meets safety objective in diabetes patients

* Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk

2:13am EDT

Severe asthma drug shows AstraZeneca promise beyond cancer

LONDON, May 22 AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.

May 22 2017

AstraZeneca sells aging beta-blocker to Recordati for $300 million

LONDON AstraZeneca has sold the European rights to its aging beta-blocker heart drug Seloken to Italy's Recordati for $300 million, as part of a continuing drive by the British drugmaker to spin off non-core assets.

May 22 2017

AstraZeneca sells ageing beta-blocker to Recordati for $300 mln

LONDON, May 22 AstraZeneca has sold the European rights to its ageing beta-blocker heart drug Seloken to Italy's Recordati for $300 million, as part of a continuing drive by the British drugmaker to spin off non-core assets.

May 22 2017

BRIEF-AstraZeneca sells rights for beat-blocker Seloken to Recordati

* Astrazeneca enters agreement with Recordati for seloken in europe

May 22 2017

BRIEF-Recordati acquires from AstraZeneca European rights to Metoprolol based products

May 22 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA:

May 22 2017

How AstraZeneca cancer drug forecasts are set to rise

LONDON Sales forecasts for AstraZeneca's all-important new cancer immunotherapy drug Imfinzi are set to rise after the drugmaker received an unexpectedly early boost for the medicine in lung cancer last week.

May 15 2017

More From Around the Web

Competitors

Earnings vs. Estimates